Latest news with #CogentBiosciences
Globe and Mail
11 hours ago
- Business
- Globe and Mail
Systemic Mastocytosis Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 8+ Companies and 8+ Therapies
DelveInsight's, 'Systemic Mastocytosis Pipeline Insight, 2025,' report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Systemic Mastocytosis pipeline landscape. It covers the Systemic Mastocytosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Systemic Mastocytosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Systemic Mastocytosis Pipeline. Dive into DelveInsight's comprehensive report today! @ Systemic Mastocytosis Pipeline Outlook Key Takeaways from the Systemic Mastocytosis Pipeline Report In May 2025, M.D. Anderson Cancer Center announced a clinical research study is to see if RAD001 can help to control the disease in patients with systemic mastocytosis (SM). The safety of this treatment will also be studied. RAD001 is designed to stop cancer cells from multiplying. It may also stop the growth of new blood vessels that help tumor growth, which may cause the tumor cells to die. In May 2025, Cogent Biosciences Inc. announced a Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL). DelveInsight's Systemic Mastocytosis Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Systemic Mastocytosis treatment. The leading Systemic Mastocytosis Companies such as AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology and others. Promising Systemic Mastocytosis Pipeline Therapies such as PA101, Avapritinib, RAD001 (Everolimus), Elenestinib, Masitinib, Avapritinib, Brentuximab vedotin, TL-895 and others. Stay ahead with the most recent pipeline outlook for Systemic Mastocytosis. Get insights into clinical trials, emerging therapies, and leading companies with Systemic Mastocytosis @ Systemic Mastocytosis Treatment Drugs Systemic Mastocytosis Emerging Drugs Profile Avapritinib: Blueprint Medicines Avapritinib is a potent and selective inhibitor of activated KIT and PDGFRA mutant kinases. In certain diseases, mutations in KIT and PDGFRA force protein kinases into an increasingly active state. Avapritinib is uniquely designed to bind and inhibit the active conformation of these proteins. Blueprint Medicines is developing AYVAKIT globally for the treatment of advanced and indolent SM. Blueprint Medicines has an exclusive collaboration and license agreement with CStone Pharmaceuticals for the development and commercialization of AYVAKIT in Mainland China, Hong Kong, Macau and Taiwan. Blueprint Medicines retains development and commercial rights for AYVAKIT in the rest of the world. The FDA granted breakthrough therapy designation to AYVAKIT for the treatment of advanced SM, including the subtypes of aggressive SM, SM with an associated hematological neoplasm and mast cell leukemia, and for the treatment of moderate to severe indolent SM. The FDA has accepted a supplemental new drug application for avapritinib for the treatment of advanced SM. The European Medicines Agency has validated a Type II variation marketing authorization application for avapritinib for the treatment of advanced SM. Masitinib: AB Sciences Masitinib's anti-mast cell properties appear particularly well-adapted to the treatment of indolent systemic mastocytosis. A reduction of mast cell activity is generated via its inhibitory action on wild-type c-Kit, Lyn and Fyn tyrosine kinases. In recognition of the critical need for new treatments, masitinib received orphan drug designation for mastocytosis from both the European Medicine Agency (EMA) and the U.S. Food and Drug Administration (FDA). AB Science initiated a confirmatory phase 3 study, with design optimized based on findings from the first phase 3 study. The Systemic Mastocytosis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Systemic Mastocytosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Systemic Mastocytosis Treatment. Systemic Mastocytosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Systemic Mastocytosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Systemic Mastocytosis market Explore groundbreaking therapies and clinical trials in the Systemic Mastocytosis Pipeline. Access DelveInsight's detailed report now! @ New Systemic Mastocytosis Drugs Systemic Mastocytosis Companies AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology and others. Systemic Mastocytosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical Molecule Type Systemic Mastocytosis Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Unveil the future of Systemic Mastocytosis Treatment. Learn about new drugs, Systemic Mastocytosis Pipeline developments, and key companies with DelveInsight's expert analysis @ Systemic Mastocytosis Market Drivers and Barriers Scope of the Systemic Mastocytosis Pipeline Report Coverage- Global Systemic Mastocytosis Companies- AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology and others. Systemic Mastocytosis Pipeline Therapies- PA101, Avapritinib, RAD001 (Everolimus), Elenestinib, Masitinib, Avapritinib, Brentuximab vedotin, TL-895 and others. Systemic Mastocytosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Systemic Mastocytosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Systemic Mastocytosis Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Systemic Mastocytosis Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Systemic Mastocytosis: Overview Pipeline Therapeutics Therapeutic Assessment Systemic Mastocytosis – DelveInsight's Analytical Perspective In-depth Commercial Assessment Systemic Mastocytosis Collaboration Deals Late Stage Products (Preregistration) Avapritinib: Blueprint Medicines Drug profiles in the detailed report….. Mid Stage Products (Phase II) PA101: Patara Pharma Drug profiles in the detailed report….. Early stage products (Phase I) DCC-2618: Deciphera Pharmaceuticals Drug profiles in the detailed report….. Inactive Products Systemic Mastocytosis Key Companies Systemic Mastocytosis Key Products Systemic Mastocytosis- Unmet Needs Systemic Mastocytosis- Market Drivers and Barriers Systemic Mastocytosis- Future Perspectives and Conclusion Systemic Mastocytosis Analyst Views Systemic Mastocytosis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
13-05-2025
- Business
- Yahoo
Why Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy Now
We recently published a list of . In this article, we are going to take a look at where Cogent Biosciences, Inc. (NASDAQ:COGT) stands against other best low priced biotech stocks to buy now. On May 8, Michael Yee, Senior Biotech Analyst at Jefferies, appeared on CNBC to discuss how tariffs and policy risks are pressuring the biotech industry, while simultaneously iterating that low valuations in the sector may present buying opportunities once the uncertainty clears. Talking about the broader impact of tariffs on the biotech sector, he said that the estimated tariff rate would be around 50%, while the negative EPS impact would be around -4-5%. According to Yee, the sector is facing several challenges that have caused significant pressure and anxiety among biotech investors. One of them is definitely sector-specific tariffs. The 50% estimation is a manageable impact for many of the biotech companies, but there are also other challenges being floated. Another factor is the most favored nations that could drop drug prices by as much as 40% to 50%, making it a related impact. Assuming all these impacts are going into place, there are definitely uncertain downside risks to the model. However, the takeaway is that many of these stocks are down more than 20-30% and, in fact, are trading at a decade-low P/E multiple. Therefore, while these uncertainties may be out there over the next few weeks or months, the stocks are expected to move higher after that. If we look back at some other stocks with tariffs, many are obviously higher off the bottoms. They have thus fallen to an attractive valuation, which is why there might be an opportunity to buy them. READ ALSO: Recession Resistant Investing: 10 Best Grocery Stocks To Buy Now and 11 Most Promising Future Stocks According to Hedge Funds. Shedding light on the most favored nation policy, Yee said it is not new. It is also not a new concept that the US, on average, pays around 40% to 50% more for drugs as compared to the basket of other, say, five to ten major developed nations. The country also gets its drugs faster, and is the home of innovation. Many of the pharmaceutical company executives over the past few weeks pointed out that most of those countries are also facing downside issues because of R&D investments, getting the drugs years later, and obviously, the countries aren't benefiting from access to any of these drugs. However, the United States government does negotiate 15-20 drugs per year and will be doing that for the next decade. We sifted through stock screeners, financial media reports, and ETFs to compile a list of 50 low-priced biotech stocks and then chose the top 10 with the highest number of hedge fund holders as of Q4 2024. We sourced the hedge fund sentiment data from Insider Monkey's database. The list is ordered in ascending order of hedge fund sentiment. Note: The data was recorded on May 9. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points (). A group of scientists in a laboratory researching a sophisticated biotechnology drug. Stock Price: $4.81 Number of Hedge Fund Holders: 38 Cogent Biosciences, Inc. (NASDAQ:COGT) is a biotechnology company that develops precision therapies for genetically defined diseases. The company's focus is on its clinical program, bezuclastinib, a selective tyrosine kinase inhibitor that potently inhibits the KIT D816V mutation and other mutations in KIT exon 17. The company ranks fifth on our list of the best low-priced biotech stocks to invest in now. On May 6, Cogent Biosciences, Inc. (NASDAQ:COGT) released its Q1 2025 earnings, reporting $245.7 million in cash which is expected to support operations until late 2026. It also highlighted significant progress in its clinical trials. The SUMMIT trial reported promising results, with bezuclastinib undergoing a 65% mean improvement in Total Symptom Score for patients with non-advanced systemic mastocytosis. Throughout 2025, Cogent Biosciences, Inc. (NASDAQ:COGT) plans to release top-line results from its SUMMIT, APEX, and PEAK trials. The commercial launch of bezuclastinib is also expected in 2026, reflecting the company's focus on advancing its pipeline of genetically driven diseases with unmet medical needs. In a report released on May 7, Louise Chen from Scotiabank maintained a Buy rating on Cogent Biosciences, Inc. (NASDAQ:COGT) and set a price target of $17.00. Overall, COGT ranks 5th on our list of the best low priced biotech stocks to buy now. While we acknowledge the potential for COGT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than COGT but trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
05-05-2025
- Business
- Yahoo
Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential?
We recently published a list of . In this article, we are going to take a look at where Cogent Biosciences, Inc. (NASDAQ:COGT) stands against other top small cap stocks to buy with biggest upside potential. On April 24, Jill Carey Hall, BofA Securities head of U.S. small/mid-cap strategy, appeared on 'Closing Bell' to talk about the impact of tariffs on small caps. She also discussed the outlook for the category, saying that the earnings backdrop is essential. When we look back a year ago, investors were excited about small caps, as the earnings were recovering and the market was coming out of the 2023 earnings recession. Everyone expected that these stocks would see double-digit earnings growth by mid-last year, outpacing large caps. That got pushed out for over a year, and now the sector has sold off a lot. While we have gotten some potential good news on tariffs, there is still a lot of uncertainty, and we are in a backdrop where earnings revisions have still been negative. She opined that she would feel more comfortable if we were in a backdrop where there was confidence in earnings recovery because last earnings season, the commentary was a lot more negative from small-cap companies than large-cap companies. So far, this earnings season is still early for small caps, but guidance in both large and small has been weak. READ ALSO: and . Hall said that the sector would see a much better picture if earnings revisions turned around with higher confidence, and not only the tariffs were better than expected but also the economic backdrop was better. However, we are also in a place where economists think the Fed will stay on hold this year, and the Russell has been very sensitive to Fed expectations. Her outlook for small caps thus points towards a more credit-sensitive environment highly tethered to Fed expectations, with no anticipation of a rate cut this year. She also highlighted that looking at corporate commentary as small-cap reporting kicks off is important. Not all small caps are created equal, even when some people consider them to be so. Hall opined that this is definitely a year where you want to be selective in small caps, focusing on stocks with strong margins amid tariff uncertainty. She favored high-quality domestic stocks, steering clear of tariff and refinancing risks and focusing on stocks with positive revisions in this broad backdrop of negative revisions. There are groups of stocks that are more sensitive to tariffs, just as there are groups that are more global and domestic. Similarly, some groups are more levered with higher refinancing risks within small caps if the rate stays higher and credit spreads stay elevated. Therefore, she reasoned that she would stick with higher-quality stocks that are more profitable and have strong operating margins. Stocks with these characteristics have been some of the top performers within the industry amid tariff risks. From a sector perspective, if investors want to be more defensive, utilities screen well across the work, both in small and large caps. There will thus be opportunities in the segment, according to Hall, but one needs to be selective. She also expressed positive sentiments for mid-caps, which have been one of the best performers in the sector this year. They have seen much better revision trends, cleaner balance sheets, and fewer risks from potential earnings hits from tariffs than small caps because the latter have thinner margins and could see a greater hit. We sifted through stock screeners, financial media reports, and ETFs to compile a list of 30 small cap stocks and chose the top 11 with the biggest analyst upside potential as of May 2, 2025. We also included the number of hedge fund holders as of Q4 2024, which we sourced from Insider Monkey's database. The list is presented in ascending order of stocks' upside potential. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points (). A group of scientists in a laboratory researching a sophisticated biotechnology drug. Market Cap: $641.01 million Analyst Upside: 207.10% Number of Hedge Fund Holders: 38 Cogent Biosciences, Inc. (NASDAQ:COGT) is a biotechnology company that develops precision therapies for genetically defined diseases. The company's focus is on its clinical program, bezuclastinib, a selective tyrosine kinase inhibitor that potently inhibits the KIT D816V mutation and other mutations in KIT exon 17. On March 10, the company received a Buy and a $17.00 price target from Scotiabank analyst Louise Chen. Piper Sandler analyst Allison Bratzel also maintained a Buy rating on Cogent Biosciences, Inc. (NASDAQ:COGT) on March 7, setting a price target of $24.00. The company has a strong cash balance and an emerging pipeline of potentially best-in-class targeted therapies, positioning it to have a transformative 2025. It plans to submit its first NDA for its clinical program, bezuclastinib, by the end of 2025. Cogent Biosciences, Inc. (NASDAQ:COGT) is the fifth-best small-cap stock to buy with the biggest upside potential. Analyst Robert Burns from H.C. Wainwright also reiterated a Buy rating on the company on February 28, keeping the price target at $14.00. He said the updated results from the SUMMIT trial showed considerable improvements in symptom severity. The trial evaluated bezuclastinib in non-advanced systemic mastocytosis. MS2D2, the novel patient-reported outcome measurement scale, reflected notable mean improvements in overall symptom severity from baseline at various intervals, highlighting the drug's efficacy and supporting the optimistic future outlook. Overall, COGT ranks 5th on our list of top small cap stocks to buy with biggest upside potential. While we acknowledge the potential for COGT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than COGT but trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
20-04-2025
- Business
- Yahoo
Cogent Biosciences (COGT): Among the Most Promising Penny Stocks According to Analysts
We recently published a list of the . In this article, we are going to take a look at where Cogent Biosciences, Inc. (NASDAQ:COGT) stands against other promising penny stocks. Solus' Dan Greenhaus, and Invesco's Brian Levitt together appeared on CNBC's 'Closing Bell' on April 15 to talk about tariffs, market uncertainty, and risk concerns. The discussion started with Dan Greenhaus expressing his belief that many worst-case scenarios are already priced into the market. He acknowledged that he's cautious but not overly worried. He pointed out recent events, like the exemptions on auto part imports and the 90-day delay on tariff implementation, as evidence that President Trump is listening to advisors and avoiding pushing toward extreme outcomes. Greenhaus attributed these actions to the rebound seen in the stock market. At the same time, he agreed that the administration has been rather inconsistent, in the context of Morgan Stanley's comment that investors should prepare for more inconsistencies. But he argued that many investors are assuming scenarios closer to the worst rather than the best. He emphasized that while frightening predictions about skyrocketing prices are taking over media right now, these scenarios are unlikely to materialize. Brian Levitt built on Greenhaus' optimism while acknowledging the ongoing uncertainty as well. He attributed this uncertainty to the reliance on decisions from the White House rather than traditional policy mechanisms. He compared the current situation to 2018 when markets fell 20% in a quarter before rebounding due to trade pauses and Fed intervention. He cautioned that the current S&P 500 multiples are not at recession levels so there are potential downside risks if uncertainty remains. While Levitt thinks that business investment and consumer confidence metrics show signs of prolonged volatility, Greenhaus further emphasizes that periods of heightened uncertainty often end up presenting long-term investment opportunities. He acknowledged risks such as sudden tariff increases but also encouraged investors to take advantage of these moments when risk premiums rise. We sifted through the Finviz stock screener to compile a list of the top penny stocks that were trading below $5 and had the highest analysts' upside potential (at least 40%). The stocks are ranked in ascending order of their upside potential. We have also added the hedge fund sentiment for each stock, as of Q4 2024, which was sourced from Insider Monkey's database. Note: All data was sourced on April 15. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A group of scientists in a laboratory researching a sophisticated biotechnology drug. Share Price as of April 15: $4.58 Number of Hedge Fund Holders: 38 Average Upside Potential as of April 15: 249.34% Cogent Biosciences, Inc. (NASDAQ:COGT) is a biotech company that develops precision therapies for genetically defined diseases. Its lead product candidate is bezuclastinib (CGT9486), which is a selective tyrosine kinase inhibitor in a Phase 3 trial. It is designed to target mutations within the KIT receptor tyrosine kinase, which includes the KIT D816V mutation that drives systemic mastocytosis (SM), as well as other mutations found in patients with advanced gastrointestinal stromal tumors. Cogent has a cash position worth $312 million, which will sustain its operations into late 2026. Its R&D expenses rose to $62 million in Q4 2024 and $232.7 million for the full year due to the accelerated development of Bezuclastinib and other research programs. In February, Cogent presented promising updates from the SUMMIT and APEX trials at the American Society of Hematology (ASH) meeting. It showed improvements in non-advanced SM and encouraging results in advanced SM patients. In the SUMMIT, patients on 100 mg of bezuclastinib showed a 56% average improvement in symptoms after 24 weeks. In the APEX trial, bezuclastinib achieved a 52% overall response rate (ORR) per mIWG criteria. Cogent Biosciences, Inc. (NASDAQ:COGT) expects top-line results from the SUMMIT trial in July 2025 and the APEX trial in H2 2025. It plans to submit the first NDA for bezuclastinib by the end of 2025. Overall, COGT ranks 4th on our list of the most promising penny stocks according to analysts. While we acknowledge the growth potential of COGT, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than COGT but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
29-03-2025
- Business
- Yahoo
We're Keeping An Eye On Cogent Biosciences' (NASDAQ:COGT) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. So, the natural question for Cogent Biosciences (NASDAQ:COGT) shareholders is whether they should be concerned by its rate of cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). Let's start with an examination of the business' cash, relative to its cash burn. The end of cancer? These 15 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. A company's cash runway is calculated by dividing its cash hoard by its cash burn. As at December 2024, Cogent Biosciences had cash of US$287m and no debt. Looking at the last year, the company burnt through US$208m. That means it had a cash runway of around 17 months as of December 2024. While that cash runway isn't too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. Depicted below, you can see how its cash holdings have changed over time. View our latest analysis for Cogent Biosciences Cogent Biosciences didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. Over the last year its cash burn actually increased by 33%, which suggests that management are increasing investment in future growth, but not too quickly. However, the company's true cash runway will therefore be shorter than suggested above, if spending continues to increase. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company. While Cogent Biosciences does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn. Since it has a market capitalisation of US$731m, Cogent Biosciences' US$208m in cash burn equates to about 29% of its market value. That's not insignificant, and if the company had to sell enough shares to fund another year's growth at the current share price, you'd likely witness fairly costly dilution. On this analysis of Cogent Biosciences' cash burn, we think its cash runway was reassuring, while its increasing cash burn has us a bit worried. Even though we don't think it has a problem with its cash burn, the analysis we've done in this article does suggest that shareholders should give some careful thought to the potential cost of raising more money in the future. Separately, we looked at different risks affecting the company and spotted 3 warning signs for Cogent Biosciences (of which 1 is a bit concerning!) you should know about. If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
